PT  - JOURNAL ARTICLE
AU  - Kelly Charniga
AU  - Nina B. Masters
AU  - Rachel B. Slayton
AU  - Lucas Gosdin
AU  - Faisal S. Minhaj
AU  - David Philpott
AU  - Dallas Smith
AU  - Shannon Gearhart
AU  - Francisco Alvarado-Ramy
AU  - Clive Brown
AU  - Michelle A. Waltenburg
AU  - Christine M. Hughes
AU  - Yoshinori Nakazawa
TI  - Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak
AID  - 10.1101/2022.06.22.22276713
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.22.22276713
4099  - http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.short
4100  - http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.full
AB  - Monkeypox is a zoonotic disease endemic in Central and West Africa. In May 2022, an outbreak of monkeypox characterized by human-to-human transmission was detected in multiple non-endemic countries. We estimated the incubation period for monkeypox using information from 22 probable (N = 1) and confirmed (N = 21) monkeypox cases in patients reported in the United States through June 6, 2022. We pooled U.S. patient data with the data from 18 confirmed cases in patients reported from the Netherlands through May 31, 2022. The mean incubation period from exposure to first symptom onset was 7.6 days (95% credible interval: 6.2 – 9.7), and the 95th percentile was 17.1 days (95% CrI: 12.7–24.3). These findings align with current CDC recommendations for monitoring close contacts of people with monkeypox for 21 days after their last exposure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the U.S. Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy (45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. R code is provided as supplementary material in a Word document.